The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency
Our findings confirm the rarity of IgAN, albeit the most common type of glomerulonephritis. They underscore a robust correlation between biopsy rates and IgAN incidence, influenced by healthcare access and quality. The COVID-19 pandemic's temporary suppression of biopsy rates in 2020 suggests potential delays in IgAN diagnosis, warranting further investigation into the long-term effects.
Authors
- Jürgen Floege (ORCID: https://orcid.org/0000-0002-8763-828X)
- Moise Turkson
- Nicholas J.A. Webb (ORCID: https://orcid.org/0000-0001-8572-5446)
- Nadine Kubesch
- Sigrid Behr
- Dmitrij Kollins
- Bart Maes (ORCID: https://orcid.org/0000-0001-5084-5130)
- Jocelyn Buisker
Institutions
- Novartis (Switzerland) (CH)
- Cognizant (United States) (US)
- Cognizant (United Kingdom) (GB)
- Universitätsklinikum Aachen (DE)
- AZ Delta (BE)
- Intuit (United States) (US)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1093/ckj/sfaf068
- Citations
- 2
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Novartis Pharma